Videos

Mark J. Levis, MD, PhD, discusses the ideal way to use quizartinib to treat a patient with an FLT3-ITD mutation in acute myeloid leukemia (AML).

Brian G.M. Durie, MD, chairman, International Myeloma Foundation (IMF), hematologist/oncologist, Cedars-Sinai Medical Center, Los Angeles, California, discusses the Black Swan Research Initiative® of the IMF and a paradigm shift in the treatment of multiple myeloma.

Lawrence N. Shulman, MD, discusses molecular testing.

Harriet Kluger, MD, associate professor of medicine (medical oncology), associate director, Hematology/Oncology Fellowship Program, Yale Cancer Center, comments on the changing landscape of immunotherapies for the treatment of melanoma.

Elizabeth Garner, MD, MPH, vice president, Clinical Affairs, Preventive Care, Myriad Genetics, discusses the Myriad myRisk Hereditary Cancer Test.

James J. Hsieh, MD, PhD, medical oncologist, Memorial Sloan-Kettering Cancer Center, discusses emerging treatment options for patients with kidney cancer.

Chandra P. Belani, MD, discusses the VEGF-targeted agent nintedanib (BIBF 1120).

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan-Kettering Cancer Center, discusses the differences between the CAR-modified T cells of three institutions.

Mike Thompson, MD, PhD, from Stillwaters Cancer Support Services, discusses oncologists’ use of and attitudes towards Twitter.

Vicki Keedy, MD, Assistant Professor of Medicine, Clinical Director, Sarcoma Program, Vanderbilt-Ingram Cancer Center, discusses the cytotoxic chemotherapy TH-302.

Laura J. Esserman, MD, from UCSF Helen Diller Family Comprehensive Cancer Center, discusses the I-SPY 2 trial, a clinical trial for women with newly diagnosed, locally advanced breast cancer.

Adam Brufsky, MD, PhD, FACP, discusses the tnAcity trial, which is aimed to clarify how best to use existing drugs in patients with triple-negative breast cancer.

María-Victoria Mateos, MD, PhD, from the University Hospital of Salamanca, Salamanca, Spain, discusses the design and results of a phase II trial that she presented at the 2013 American Society of Hematology Meeting.

Bilal Piperdi, MD, discusses the recent advancements in non-small cell lung cancer treatment and what the future might bring.

Richard S. Finn, MD, associate professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, discusses the use of tivantinib and regorafenib for the treatment of patients with liver cancer.

Edith A. Perez, MD, discusses the antibody drug conjugate T-DM1 (trastuzumab emtansine; Kadcyla) as a treatment for patients with breast cancer.

Richard R. Furman, MD, Richard A. Stratton Assistant Professor in Hematology and Oncology, Weill Cornell Medical College, gives an overview of the efficacy and safety of idelalisib and rituximab for previously treated CLL.

Matthew D. Galsky, MD, discusses targeted therapy treatments for bladder cancer.

Kristi McIntyre, MD, a physician with Texas Oncology, discusses the results of a phase II, multicenter, single-arm study looking at eribulin mesylate as first-line therapy for locally recurrent or metastatic HER2-negative breast cancer.

Evan Y. Yu, MD, associate professor, Department of Medicine, Division of Oncology, Seattle Cancer Care Alliance, discusses the utility of PET imaging for the treatment of patients with prostate cancer.

Matthew Burke, MBA, RN, MSN, APRN-BC, Oncology Nurse Practitioner/Melanoma and Renal Cell Carincoma, Yale New Haven Hospital, discusses the difference between adverse events caused by chemotherapy and immunotherapy.

Matthew J. Ellis, MD, PhD, discusses the ongoing phase III FALCON trial.

Alice T. Shaw, MD, PhD, from Massachusetts General Hospital, discusses the advent of more potent ALK inhibitors such as LDK378 and the treatment of ALK-positive lung cancer patients with crizotinib.

Nicholas Turner, PhD, consultant medical oncologist, The Royal Marsden Hospital, London, discusses the PALOMA-3 trial, which studied palbociclib combined with fulvestrant for the treatment of patients with hormone receptor-positive, HER2-negative metastatic breast cancer after endocrine failure.

Ayalew Tefferi, MD, hematologist, Mayo Clinic, Rochester, Minnesota, discusses the outlook for JAK inhibitors for patients with myelofibrosis.

Marcia S. Brose, MD, PhD, describes the DECISION trial, which analyzed the efficacy of sorafenib in differentiated thyroid cancer.

Bradley Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, discusses clinical trial endpoints and individualizing treatment in patients with ovarian cancer.

William Kevin Kelly, DO, professor of medical oncology and urology, Thomas Jefferson University, discusses the possibility of preselecting which castration-resistant prostate cancer (CRPC) patients will be sensitive to chemotherapy or hormone therapy.

Margaret A. Tempero, MD, director, Pancreas Center, University of California, San Francisco, discusses the role of radiation for the treatment of pancreatic cancer.

Mark J. Levis, MD, PhD, discusses the difficulty of treating a patient with a FLT3-ITD mutation in acute myeloid leukemia.